Why the study?
Does a single-capsule fixed-dose combination of amlodipine/benazepril improve medication adherence in hypertensive subjects compared to separate components?
Population
5,732 hypertensive subjects (mean age 53 years, 50% male) enrolled in a managed care organization.
Comparison
Single-capsule, fixed-dose combination of… vs Regimen including an angiotensin-converting…
Design
Cohort
Key result
A once-daily, single-capsule, fixed-dose combination of amlodipine/benazepril significantly improved medication adherence compared to separate components (80.8% vs. 73.8%; p<0.001).
Authors
Loading...
May boost adherence with amlodipine/benazepril; observational data leave open outcome benefits and need RCT confirmation.
Cohort (n=5,732)
Does a single-capsule fixed-dose combination of amlodipine/benazepril improve medication adherence in hypertensive subjects compared to separate components?
Absolute Event Rate: 80.8% vs 73.8%
p-value: p=<0.001
A fixed-dose combination of amlodipine and benazepril significantly improves medication adherence and reduces cardiovascular-related care costs compared to taking the medications separately.
Taylor et al. (2003) conducted a cohort in Hypertension (n=5,732). Single-capsule, fixed-dose combination of amlodipine besylate/benazepril HCl vs. Angiotensin-converting enzyme inhibitor and a dihydropyridine calcium channel blocker as separate drugs was evaluated on Medication adherence measured by the medication possession ratio (p=<0.001). A once-daily, single-capsule, fixed-dose combination of amlodipine/benazepril significantly improved medication adherence compared to separate components (80.8% vs. 73.8%; p<0.001).